Benzene is a known human leukemogen that is widely used as an industrial solvent in industries such as oil, shipping, automobile repair, and shoe manufacturing and is also a component of cigarette smoke, automobile exhaust, and gasoline. Therefore, large populations of people are exposed to benzene either occupationally or through environmental contamination. Chronic exposure to benzene in humans and animals has been correlated with the development of blood disorders such as bone marrow depression, aplastic anemia, and acute myelogenous leukemia (Snyder, 2007) .
Leukemia is one of the most prevalent childhood cancers accounting for 35% of all cancers diagnosed in children less than 5 years of age. In addition, the incidence of childhood leukemia is increasing in North America and Europe (Dreifaldt et al., 2004; Gurney et al., 1996; McNally et al., 2001; Steliarova-Foucher et al., 2004) . The precise causes of childhood leukemias are unknown, but it has been hypothesized that in utero exposure to environmental pollutants, such as benzene, may play a primary role. Epidemiological studies support this hypothesis and have shown an association between maternal exposure to sources of benzene and the development of childhood hematopoietic malignancies (Brosselin et al., 2009; Crosignani et al., 2004; Nordlinder and Jarvholm, 1997; Steffen et al., 2004) . In humans, benzene has been detected in fetal cord blood at levels equal to or greater than those found in maternal blood, indicating that benzene can cross the placenta and may accumulate in the fetal-placental unit (Dowty et al., 1976) .
Transplacental transfer of benzene has also been demonstrated in pregnant mice exposed to radiolabeled benzene, and accumulation of radioactivity was detected in embryonic hematopoietic tissues (Ghantous and Danielsson, 1986 ). In addition, in utero exposure to low concentrations of benzene in mice alters the growth of myeloid and erythroid progenitor cells in fetal tissue with offspring showing sustained hematopoietic alterations up to at least 6 weeks after birth (Keller and Snyder, 1986) . Therefore, in humans and mice, it is clear that in utero exposure to benzene targets hematopoietic tissue and has long-term effects on the offspring's hematopoietic system; however, the mechanisms behind benzene-induced fetal hematotoxicity are unknown.
There is a growing body of evidence indicating that many chemical-initiated fetal toxicities are mediated by embryonic bioactivation of xenobiotics to free radical intermediates that can generate reactive oxygen species (ROS) (Wells et al., 2005) . ROS can play physiological roles in signal transduction but in excess can contribute to fetal toxicity by dysregulation of signal transduction and/or by oxidative damage to cellular macromolecules (lipids, proteins, DNA, RNA, and carbohydrates). In addition, it is thought that the embryo may be particularly sensitive to changes in cellular redox status since antioxidative defense mechanisms are considerably lower in the embryo compared to adults . A mechanistic study in mice has indicated that ROS may play a major role in benzene-mediated fetal hematotoxicity (Wan and Winn, 2008) . This study showed that pretreatment with the antioxidative enzyme catalase can attenuate benzene-induced decreases in fetal reduced to oxidized glutathione ratios (GSH:GSSG) as well as benzene-induced changes in redoxsensitive signaling pathways crucial in regulating hematopoiesis. However, this study used an acute high concentration of benzene (800 mg/kg), which may not be reflective of environmental exposures in humans. In addition, this study did not directly measure the production of ROS and concludes that benzene metabolism by glutathione S-transferase instead of oxidative stress could be responsible for the observed decreases in fetal GSH:GSSG ratios. Therefore, whether ROS play a role in benzene-induced fetal hematotoxicity is still uncertain. Furthermore, whether the production of ROS after in utero benzene exposure is responsible for benzene-induced dysregulation of fetal hematopoietic progenitor cell growth is also unknown. Therefore, the aim of this study was to evaluate the role of ROS as a mechanism of benzene-induced aberrant fetal hematopoietic progenitor cell growth after exposure to chronic low levels of benzene during pregnancy in mice.
MATERIALS AND METHODS
Animals. Seven-to 9-week-old female C57Bl/6N mice were obtained from Taconic Farms (Germantown, NY). Animals were acclimated for 1 week prior to use and were housed in a temperature-controlled room with a 12-h light:dark cycle (lights on from 6 A.M. to 6 P.M.). Mice were allowed autoclaved standard rodent chow (Purina Rodent Chow; Ralston Purina International, Ontario, Canada) and tap water ad libitum. A maximum of three females were housed with one male overnight and assessed for the presence of a vaginal plug the following morning. The presence of a vaginal plug was designated gestational day (GD) 1. All animals were treated in accordance with the guidelines of the Canadian Council on Animal Care. Experimental procedures were approved by the Queen's University Animal Care Committee.
Treatment protocol. Sixteen pregnant mice were exposed to either Mazola corn oil (vehicle) or 200 or 400 mg/kg benzene (Sigma-Aldrich Canada Ltd, Ontario, Canada) on GD 8, 10, 12, and 14 by ip injection. Benzene injections on GD 8, 10, 12, and 14 were chosen in order to encompass hematopoietic stem cell (HSC) emergence (approximately GD 10 in the aorta-gonad-mesonephros) and fetal liver HSC expansion (GD 11 to birth) (Dzierzak, 2005) . In another set of experiments, 17 mice were pretreated ip with either 25 kU/kg polyethylene glycol PEG-catalase (Sigma-Aldrich Canada Ltd) dissolved in PBS or PBS alone 16 h prior to each benzene or corn oil injection. Mice were euthanized by cervical dislocation 2, 4, or 48 h after the GD 14 injection and fetal livers were collected for analysis. Administration of 25 kU/kg PEG-catalase has previously been shown to significantly increase embryonic catalase activity (Winn and Wells, 1999) .
Colony formation assays. This assay allows for accurate assessment of the number of hematopoietic progenitor cells present in the cell sample since each progenitor cell type will produce its own unique colony that can be morphologically identified and counted under a light microscope (Dobo et al., 1995) . The progenitor cell types measured in this study were colony-forming unit-erythroid (CFU-E), blast-forming unit-erythroid (BFU-E), colony-forming unit-granulocyte/monocyte (CFU-GM), colony-forming unit-granulocyte (CFU-G), and colony-forming unit-monocyte (CFU-M).
Three GD 16 fetal livers were collected from each of 16 dams. Fetal livers were immersed in Iscove's Modified Dulbecco's Medium (IMDM; Invitrogen, Burlington, Ontario, Canada) and single cell suspensions were obtained by gently passing the tissue through a 21-gauge needle. Cells were at least 90% viable as tested by the trypan blue exclusion assay. Nucleated cells were counted using 3% acetic acid with methylene blue (Stem Cell Technologies, Vancouver, British Columbia, Canada) and were plated in 35-mm culture dishes at a concentration of either 1 3 10 5 or 1 3 10 4 cells/ml in methylcellulose medium containing either erythropoietin (to detect erythroid CFU-E and BFU-E colonies) or stem cell factor, interleukin (IL)-3, and IL-6 (to detect myeloid CFU-G, CFU-M, and CFU-GM colonies), respectively (MethoCult M3334 and M3534; Stem Cell Technologies). Cultures were placed in a humidified incubator with 5% CO 2 at 37°C. Erythroid CFU-E colonies (containing~10-30 cells) and BFU-E colonies (containing greater than 30 cells) were counted 3 days after incubation. Myeloid CFU-G, CFU-M, and CFU-GM colonies containing at least 30 cells were counted 12 days after incubation.
ROS detection. Three GD 14 fetal livers were collected from each of 17 dams. Single cell suspensions in IMDM were obtained by passing the liver tissue gently through a 21-gauge needle. Cells (1 3 10 6 cells in 100 ll PBS) were incubated in 4 lg/ml PerCp/Cy5.5-conjugated anti-mouse CD117 (c-kit) antibody (Biolegend, San Diego, CA) for 30 min and 0.3lM of the ROS-sensitive fluorescent probe 5-(and-6)-chloromethyl-2#,7#-dichlorodihydrofluorescein diacetate (DCFDA) (Invitrogen) for 15 min in the dark at room temperature. Cells were then washed three times with PBS and resuspended in PBS containing 5 lg/ml propidium iodide (PI) (to allow for exclusion of dead cells from the analysis) (Sigma-Aldrich Canada Ltd). Fluorescence intensities of PerCP/Cy5.5, DCFDA, and PI were measured using flow cytometry.
Sample preparation for analysis of oxidative stress markers and Inhibitor of NF-kB-alpha protein levels. Maternal and fetal liver tissues were homogenized in lysis buffer (150mM NaCl, 2% SDS, and 20mM Tris, pH 7.6) and sonicated for 10 s. The lysate was subsequently centrifuged at 21,000 RCF ¼ 21,000 3 g for 10 min and supernatant collected. Protein concentration was determined using the Lowry Assay (Bio-Rad DCF protein determination kit; Bio-Rad, Hercules, CA). Samples were kept at À80°C until use.
Western blot analysis. Fifteen micrograms of prepared sample was separated by SDS-polyacrylamide gel electrophoresis in a 10% polyacrylamide gel and transferred to a polyvinylidene difluoride carrier membrane (Millipore Co., Bedford, MA). Membranes were blocked in 5% milk in tris buffered saline with tween (TBS-T) (25mM Tris-HCl, 140mM NaCl, 2mM KCl, and 0.05% [vol/vol] Tween-20) for 1 h and then incubated in 1:500 mouse monoclonal anti-4-hydroxynonenol (4-HNE) (Japan Institute for the Control of Aging, Shizuka, Japan), 1:500 rabbit polyclonal anti-nitrotyrosine (Molecular Probes, Eugene, OR), 1:1000 rabbit monoclonal anti-inhibitor of NF-kB-alpha (IjB-a) (New England Biolabs Ltd, Pickering, ON), or 1:1000 mouse monoclonal antib-actin (Sigma-Aldrich Canada Ltd) in 0.5% milk (4-HNE, nitrotyrosine, and b-actin) or 0.5% bovine serum albumin (IjB-a) at 4°C overnight. Membranes were washed in TBS-T and then incubated in horseradish peroxidaseconjugated anti-mouse (1:4000) or anti-rabbit (1:10,000 for nitrotyrosine and 1:4000 for IjB-a) IgG secondary antibody (GE Healthcare Bio-Sciences Inc., Quebec, Canada) in 0.25% milk for 1 h. Membranes were washed with TBS-T and developed using the ECL chemiluminescence detection system (GE Healthcare Bio-Sciences Inc.) and Kodak X-OMAT scientific imaging film (PerkinElmer, Waltham, MA). Immunoblot bands were quantified by scanning blots and measuring their relative optical density (ROD) using ImageJ software (Abramoff et al., 2004) . ROD measurements of 4-HNE, nitrotyrosine, or IjB-a were normalized to b-actin content for each well. Blots initially probed for 4-HNE were stripped for 25 min at 55°C using stripping buffer (0.7% [vol/vol] 208 BADHAM AND WINN 2-mercaptoethanol, 2% [vol/vol] SDS, and 62.5mM Tris-HCl, pH 6.7) and then used to probe for nitrotyrosine. Membranes were then stripped again and probed for b-actin.
Reduced to oxidized glutathione determination. Reduced to oxidized glutathione ratios were measured as previously described (Wan and Winn, 2008) . Briefly, 50 lg of maternal liver tissue and three fetal livers were collected per pregnant dam 2, 4, and 24 h after benzene exposure on GD 14. Maternal and fetal liver tissues were homogenized in 5% (wt/vol) 5-sulfosalicyclic acid, centrifuged for 2 min at 12,000 RCF ¼ 21,000 3 g, supernatant was collected, and samples were kept at À80°C until analysis. A 50-ll aliquot of each sample was incubated with 1.5 ll of 2-vinylpyridine and 10 ll of 10% triethanolamine for 1 h to conjugate GSH and allow for GSSG readings. To each conjugated and nonconjugated sample, 190 ll of reaction mix (1mM EDTA, 100mM Na 2 H 2 PO 4 , 0.15mM 5,5#dithiobis[2-nitrobenzoic acid], 0.2mM NADPH, and 1 U/ml glutathione reductase) was added. Samples were read in a 96-well plate in triplicate. Kinetic readings at 405 nm for 2 min were taken with a Bio-Tek Synergy HT multidetection microplate reader with KC4 v4 software (Bio-Tek Instruments Inc., Winooski, VT). A standard curve using 0-150 pmol of GSSG per well was run in conjunction with samples. GSH content was determined by multiplying values by 2 to obtain GSH t and then subtracting 2GSSG from GSH t . All reagents were obtained from Sigma-Aldrich Canada Ltd.
Statistical analysis. Results were analyzed using a computerized statistical program (GraphPad Prism 4.0). Data from flow cytometric analysis of DCFDA fluorescence, optical density of Western blot analysis of fetal 4-HNE and nitrotyrosine products, and reduced to oxidized glutathione ratios of fetal liver tissue were analyzed by a two-way ANOVA followed by a Bonferoni post hoc test. All other data sets were analyzed by a one-way ANOVA followed by a Dunnett's post hoc test. Differences were considered statistically significant when p < 0.05.
RESULTS

Administration of Benzene Does Not Cause Significant Maternal or Fetal Toxicity
The two treatment protocols used in this study did not produce significant benzene-dependent maternal or fetal toxicity as measured by maternal weight gain, litter size, resorption number, and fetal weight throughout the treatment protocols (Table 1) .
In Utero Benzene Exposure Alters Fetal Colony Formation
To determine whether in utero exposure to benzene alters colony numbers of fetal hematopoietic progenitor cells, we used hematopoietic culture assays to detect the proliferation and differentiation ability of these cells. These assays allow for the identification of hematopoietic progenitor cells at distinct stages of differentiation as well as provide a measurement of hematopoietic progenitor cell frequency in tissues. Results from these assays showed that in utero exposure to 200 mg/kg benzene on GD 8, 10, 12, and 14 significantly increased the number of CFU-E (p < 0.01), BFU-E (p < 0.001), CFU-GM (p < 0.05), and CFU-G (p < 0.001) colonies and significantly decreased the number of CFU-M (p < 0.05) colonies in hematopoietic tissue of GD 16 C57Bl/6N fetuses (Fig. 1) . Furthermore, in utero exposure to 400 mg/kg benzene on GD 8, 10, 12, and 14 significantly increased the number of CFU-E (p < 0.05) and CFU-G (p < 0.05) colonies only (Fig. 1) . It is important to note that there was no significant cell death detected in fetal liver tissue exposed to either 200 or 400 mg/kg benzene compared to control tissue as measured by the trypan blue exclusion assay. Since 200 mg/kg benzene exposure significantly affected more progenitor cell types compared to 400 mg/kg benzene exposure, the PEG-catalase pretreatment study was carried out using in utero exposure to 200 mg/kg benzene.
In Utero Benzene Exposure Increases Fetal ROS Production
To determine whether in utero exposure to 200 mg/kg benzene causes an increase in ROS in fetal hematopoietic tissue, we used flow cytometric analysis of DCFDA fluorescence in CD117 þ cells (expressed on multipotent HSC, progenitors committed to myeloid and erythroid lineages, and T-and B-cell precursors). A two-way ANOVA with a Bonferoni post hoc test detected a significant increase in mean DCFDA fluorescence in CD117 þ /PI À cells isolated from fetal livers 2 h after exposure to 200 mg/kg benzene on GD 14 (p < 0.001; Fig. 2A ). Pretreatment with PEG-catalase, but not PBS, 16 h prior to each benzene injection completely protected against the benzene-induced increase in ROS formation. It is important to note that there were no significant changes in the percentage of cells staining positive for PI (cell death marker) in any treatment group (Fig. 2B) .
PEG-Catalase Protects against Benzene-Induced Alterations in Colony Formation
Since 25 kU/kg PEG-catalase pretreatment was sufficient to block benzene-induced ROS production, we sought to determine if pretreatment with PEG-catalase could prevent benzene-induced alterations in fetal hematopoietic progenitor cell growth. Our results show that pretreatment with PEGcatalase on GD 7, 9, 11, and 13 (16 h prior to each oil or 200 mg/kg benzene injection) significantly inhibits benzeneinduced changes in colony numbers in all four progenitor cell types (p < 0.05) (Fig. 3) . Pretreatment with PBS only prior to benzene exposure did not affect benzene-induced alterations in colony number.
In Utero Benzene Exposure Does Not Alter Oxidative Stress Markers in Fetal Tissue
Since in utero exposure to 200 mg/kg benzene caused a significant increase in ROS (indicated by an increase in mean DCFDA fluorescence) in fetal liver tissue, we wanted to determine whether this was correlated with signs of oxidative stress. Reduced to oxidized glutathione ratios and levels of 4-HNE and nitrotyrosine products (markers of oxidative damage by lipid peroxidation and peroxynitrite, respectively) were measured in maternal (positive control) and fetal liver tissue. As expected, administration of 200 mg/kg benzene significantly increased 4-HNE and nitrotyrosine levels in maternal liver tissue (positive control) 2 h after exposure (Fig. 4) confirming earlier findings . However, in fetal liver tissue, densitometry analysis indicated that in utero exposure to 200 mg/kg benzene did not significantly alter levels of these products compared to vehicle treated controls 2, 4, or 24 h after benzene exposure on GD 14 (Fig. 4) . As expected, reduced to oxidized glutathione levels were significantly decreased in maternal liver tissue (positive control) 2 h after exposure to 200 mg/kg benzene (Fig. 5 ). 
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However, ratios were unchanged in fetal liver tissue 2, 4, and 24 h after in utero exposure to 200 mg/kg benzene (Fig. 5) .
In Utero Benzene Exposure Decreases Protein Levels of IjB-a in Fetal Liver Tissue
Considering that in utero exposure to 200 mg/kg benzene caused a significant increase in ROS, but without subsequent increases in markers of oxidative stress, we wanted to determine if in utero exposure to benzene could affect redoxsensitive signaling pathways as a potential mechanism of benzene-induced fetal hematotoxicity. Protein levels of the NFjB inhibitor, IjB-a, were measured by Western blot analysis in fetal liver tissue. Densitometry revealed that in utero exposure to 200 mg/kg benzene significantly reduced fetal liver IjB-a protein levels 2 h after exposure (p < 0.01) (Fig. 6) . Furthermore, the benzene-induced decreases in IjB-a protein levels were prevented by maternal pretreatment with PEGcatalase.
DISCUSSION
Under normal conditions, hematopoiesis is tightly regulated so that cells undergoing the most rapid turnover and thus having the greatest potential for neoplastic transformation are committed to terminal differentiation or apoptosis. However, some chemical agents can disrupt this process and cause Quantitative analysis of the optical density (OD) obtained from the blots showed no significant change in 4-HNE or nitrotyrosine levels in fetal liver tissue at 2, 4, or 24 h. As expected, there was a significant increase in both 4-HNE and nitrotyrosine levels in maternal liver tissue 2 h after exposure to 200 mg/kg benzene (p < 0.01). *Statistically significant from PBS þ oil control. nitroTYR, nitrotyrosine; BZ, benzene. aberrant hematopoietic cell proliferation and increase the risk of carcinogenesis (Preston-Martin et al., 1990) . Keller and Snyder (1986) found that in utero exposure to low concentrations of benzene in mice caused a significant increase in fetal liver BFU-E and CFU-E colonies on GD 16. Our results are consistent with these findings and also show for the first time that in utero exposure to benzene also affects CFU-G, CFU-M, and CFU-GM colonies. Studies in adult humans exposed to benzene have detected changes in the less differentiated progenitor cell CFU-GEMM, which gives rise to CFU-G, CFU-M, CFU-GM, and BFU-E (Lan et al., 2004) . Considering that in utero exposure to benzene affected all progenitor cell types that arise from CFU-GEMM cells, our data suggest that toxicity to this progenitor cell type is likely. Whether alterations in BFU-E, CFU-G, CFU-M, and CFU-GM reflect leukemic events that may be occurring in these cells themselves or in CFU-GEMM cells is still uncertain and remains to be clarified.
Interestingly, the benzene-induced changes in colony formation numbers that we observed did not follow a typical dose-response outcome. However, we are not the first group to observe an unusual dose response with benzene toxicity. Bone marrow cells from adult mice exposed to 200 mg/kg benzene had higher levels of nitrotyrosine products compared to those exposed to 400 mg/kg benzene . A similar trend was reported for benzene-induced 8-hydroxy-2#-deoxyguanosine and elevation of micronuclei in adult mouse bone marrow (Chen et al., 1994; Kolachana et al., 1993) . A model evaluating benzene metabolism in mouse liver microsomes showed that as benzene concentrations increase, metabolism of phenol to hydroquinone, a more toxic benzene metabolite, decreases due to competition for CYP450 activation (Schlosser et al., 1993) . In addition, mice and humans excrete a greater proportion of toxic metabolites when exposed to low benzene levels and excrete a greater proportion of markers of the detoxification pathway when exposed to high levels of benzene (Henderson, 1996; Rothman et al., 1998) . These results suggest that detoxification pathways are low affinity and high capacity, whereas toxification pathways are high affinity and low capacity. Therefore, the unusual dose response seen in our study may be explained by differences in metabolism and suggests that linear extrapolation of the toxic effects of high concentrations of benzene to lower concentrations may underestimate risk.
It is interesting that in utero exposure to benzene resulted in an increase in BFU-E, CFU-E, CFU-G, and CFU-GM but a decrease in CFU-M colony numbers in fetal liver. These observations may be explained by a difference in sensitivity to benzene toxicity between progenitor cell types that could arise from differences in bioactivation capability between cells. Alternatively, benzene-induced ROS production could affect different signaling pathways in each cell type leading to increased or decreased proliferation depending upon the affected pathways.
Benzene-induced hematotoxicity is linked to the formation of hydroxylated metabolites, such as hydroquinone and FIG. 5. Reduced to oxidized glutathione ratios (GSH:GSSG) in fetal liver and maternal liver tissue 2 h after in utero exposure to either PBS þ oil (n ¼ 4), PBS þ 200 mg/kg benzene (n ¼ 5), PEG-catalase þ oil (n ¼ 4), or PEG-catalase þ 200 mg/kg benzene (n ¼ 4). There was no significant change in GSH:GSSG in fetal liver tissue at 2, 4, or 24 h. As expected, there was a significant decrease in GSH:GSSG in maternal liver tissue 2 h after exposure to 200 mg/kg benzene (p < 0.01). *Statistically significant from PBS þ oil control. BZ, benzene. 
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BADHAM AND WINN benzoquinone. However, how these metabolites interfere with normal differentiation and proliferation of cycling hematopoietic progenitor cells is unclear, but increasing evidence indicates that the generation of ROS may be involved (Snyder, 2007) . ROS have been implicated in a number of diseases such as Alzheimer's (Nunomura et al., 2006) , teratogenesis (Wells et al., 2005) , carcinogenesis (Valko et al., 2006) , and in utero initiation and/or promotion of cancer . It is generally accepted that ROS can initiate these diseases by causing oxidative DNA damage or by interfering with redoxsensitive signaling pathways (Wan and Winn, 2006) .
Our study is the first to show that in utero exposure to benzene results in a significant increase in ROS production in CD117 þ fetal hematopoietic cells, which can be blocked by pretreatment of mice with the antioxidative enzyme PEGcatalase. These results along with our data demonstrating protection of PEG-catalase against dysregulation of hematopoietic progenitor cell growth support the production of ROS as a mechanism of benzene-induced alterations in fetal hematopoietic cells. However, we did not detect any sign of oxidative stress as measured by the presence of 4-HNE or nitrotyrosine products or reduced to oxidized glutathione ratios. Interestingly, we did detect a benzene-induced activation of the NFj-B signaling pathway (measured by a decrease in IjB-a protein levels) in fetal liver tissue, which was abrogated by pretreatment with PEG-catalase. Therefore, our results suggest that in utero exposure to low levels of benzene increases ROS in fetal hematopoietic tissue to levels insufficient to result in measurable cellular damage but adequate to activate the redoxsensitive NFj-B signaling pathway. Nuclear factor-kappalight-chain-enhancer of activated B cells (NF-jB) proteins are transcription factors that can be regulated by ROS (Bowie and O'Neill, 1997; Ghosh and Karin, 2002; Musonda and Chipman, 1998 ) and play major roles in maintaining growth and survival of hematopoietic stem and progenitor cells (Pyatt et al., 1999) . The activities of NF-jB proteins are largely regulated by specific inhibitor proteins known as the IjBs (Inhibitor of NF-jB). The binding of IjB proteins to NF-jB masks a nuclear translocation sequence and therefore sequesters the NF-jB/IjB complex in the cytoplasm. In response to an activation signal, such as ROS, IjB proteins become phosphorylated and consequently poly-ubiquitinated and degraded by the proteasome pathway resulting in the release of NF-jB proteins that can then migrate to the nucleus and activate transcription of target genes (Hayden and Ghosh, 2004) . Aberrant activation of NF-jB has been implicated in lymphoid and myeloid malignancies (Braun et al., 2006; Gilmore et al., 2004) .
Interestingly, benzene metabolite exposure has been shown to alter a number of redox-sensitive signaling pathways involved in the regulation of hematopoietic progenitor cell growth such as ERK/AP-1 (Ruiz-Ramos et al., 2005; Zheng et al., 2004) and c-Myb/Pim-1 (Wan and Winn, 2008) . Proper embryonic hematopoiesis requires precise regulation of embryonic cell signaling pathways, and abnormalities in these pathways may be detrimental to the embryo. Considering that we did not detect any signs of oxidative stress as measured by GSH:GSSG ratios, and levels of 4-HNE and nitrotyrosine products, leukemic events initiated by in utero exposure to low levels of benzene may be due to aberrant cell signaling resulting in abnormal cell proliferation and warrants further investigation.
Although the precise mechanism of how benzene metabolites cause an increase in ROS remains unclear, studies indicate that GSH may play a central role. For example, some studies have shown that ROS production can occur through redox cycling of phenoxyl radicals via the oxidation of GSH or protein thiol groups (Stoyanovsky et al., 1995) . In addition, redox cycling of GSH-hydroquinone conjugates can also enhance ROS formation (Brunmark and Cadenas, 1988; Rao, 1996) . In utero exposure to an acute high dose (800 mg/kg) of benzene has been shown to cause a decrease in fetal GSH:GSSG ratios (Wan and Winn, 2008) . However, whether this result is due to oxidative stress or conjugation with benzene metabolites is unclear. Interestingly, we did not detect a change in fetal GSH:GSSG ratios after in utero exposure to a low concentration (200 mg/kg) of benzene, however, we did detect an increase in fetal ROS. These results suggest that ROS produced in the fetal unit after exposure to low concentrations of benzene may not be through a GSH-dependent mechanism. Some studies have shown that both iron-hydroquinone complexes and a similar chelate of iron and 1,2,4-benzene triol can generate ROS in the bone marrow (Singh et al., 1994) . Considering that the fetal liver is rich in iron, the generation of ROS after in utero exposure to benzene may be through an iron-dependent mechanism.
While the doses of 200 and 400 mg/kg used for this study are relatively high, they were selected based on the pharmacokinetic pattern of noninhalation exposure to benzene. Studies have shown that noninhalational administration of benzene results in the majority of the dose being excreted or exhaled without being metabolized (Sabourin et al., 1987) . In addition, in order to model benzene-induced leukemia in humans, studies have shown that adult C57Bl/6 mice have an increased incidence of leukemia after exposure to 300 ppm inhaled benzene 6 h/day, 5 days/week for 16 weeks (Cronkite et al., 1984) . Steady-state blood benzene levels in C57Bl/6 mice exposed to 300 ppm inhaled benzene for 6 h arẽ 10.7 lg/ml (Driscoll and Snyder, 1984) . Our maternal blood benzene levels peaked 1 h after ip injection to either 200 or 400 mg/kg benzene with a mean concentration of 11.6 or 22.7 lg/ml, respectively (unpublished data). Therefore, our benzene dose and route of exposure produces blood benzene levels that are very similar to levels measured in adult C57Bl/6 mice that develop leukemia after long-term benzene exposure.
It is important to note that in humans, benzene exposure usually occurs via the inhalation route, whereas the route of exposure in this study was through ip injection, which allows for the administration of precise dosages at desired time points. Therefore, while we anticipate that the effects reported in this study would also occur after in utero exposure to benzene via the inhalation route, further studies are required to confirm this. In addition, an ip injection causes tissue damage at the site of injection, which can lead to a local immune response and therefore the generation of ROS in the peritoneum, which may confound our findings. However, considering that our control group received an ip injection (corn oil) as well, we feel that this possible confounder was adequately controlled for. It should also be noted that, although we did not observe any obvious signs of benzene-induced maternal toxicity as measured by weight gain or loss, it is possible that administration of 200 or 400 mg/kg benzene could produce maternal bone marrow depression, which could negatively impact the fetus.
In summary, our results strongly support a role for ROS and alterations in NFj-B signaling in benzene-induced hematotoxicity after in utero exposure and provide a novel model of ROS-induced alterations in fetal hematopoietic progenitor cell growth. This model can be utilized to further elucidate mechanisms of in utero-initiated benzene toxicity as well as to investigate the role of ROS in mechanisms of other xenobiotic-induced transplacental hematotoxicities. 
